Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Item
http://www.wikidata.org/entity/Q38710302
Ejaculatory dysfunction in the treatment of lower urinary tract symptomsThe link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.Pharmacologic management of non-neurogenic functional obstruction in women.Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.Stimulators and activators of soluble guanylate cyclase for urogenital disorders.Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study.Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission.
P2860

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Item
http://www.wikidata.org/entity/Q38710302
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Latest Evidence on the Use of ...... Benign Prostatic Hyperplasia.
@en
type
label
Latest Evidence on the Use of ...... Benign Prostatic Hyperplasia.
@en
prefLabel
Latest Evidence on the Use of ...... Benign Prostatic Hyperplasia.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Latest Evidence on the Use of ...... Benign Prostatic Hyperplasia.
@en
P2093
P304
P31
P356
10.1016/J.EURURO.2015.12.048
P407
P433
P478
P50
P577
P698